BPS 2025 Proceedings
WALEED DANHO YOUNG INVESTIGATOR AWARD CEREMONY & KEYNOTE
Anne Conibear
Assistant Professor
TU Wien
Posttranslational Modifications of Disordered Proteins
Peptide Showcase
Brief 15 minute presentations from companies developing peptide therapeutics and related technologies. This rapid and compressed format is designed for quick introduction between symposium participants to new technologies, and companies. Each presentation is structured to highlight the value of the technology or therapeutic being offered and the business strategy.
Timothy Craven
CEO
Insamo
Integrating computational design and display screening for ultra high-throughput cell-permeable cyclic peptide discovery.
Nicolas Gilles
senior researcher
CEA
A snake peptide toxin for treatment of kidney diseases. From bench to bedside
Stephane Roche
CEO
AdaptBio Therapeutics
ADAPT: An Emerging Platform of Antibody CDR-H3-based Scaffolds for the Discovery of Novel Classes of Protein-Protein Interaction Inhibitors
Wentao Guo
Technical Business Development – AI/ML solutions
Atombeat Inc.
Physics+AI-Guided Design and Plate-Based Synthesis Unlock >10¹² Cyclic Peptidomimetics for Cell-Permeable Inhibitor Discovery
Eric Fang
Site Head-CSO
Snapdragon Chemistry, a Cambrex Company
Liquid-phase peptide fragment manufacturing technologies and workflows using batch and flow chemistry
Benyi Li
Professor
KANSAS UNIV MEDICAL CENTER
An AR protein degrader for prostate cancer therapy
Justin Northrup
Head of R&D
ThirdLaw Molecular
Application of a 4.5 Billion Member DNA Encoded Library of Spiroligomer™ Macromolecules to Discover Low Nanomolar Binders for TNF-alpha
Christa Pawlowski
COO, EVP Research & Development
Haima Therapeutics LLC
Development of Heteromultivalent Peptide-decorated Nanoparticles for Hemorrhage Control
Will Van Treuren
Principal Scientist
Aizen Therapeutics
Mirror peptides as a novel therapeutic modality
Rashmin Savani
Co-Founder and Head, Scientific Advisory Board
Azome Therapeutics
RHAMM-derived Peptide Blocks NLRP3 Inflammasome Activation: Novel Therapy to Prevent Bronchopulmonary Dysplasia
Paul Wright
Senior Director, API Development and Manufacturing
Kailera Therapeutics
Kailera: Advancing Next-Generation Therapies for Obesity
Peptides in the Clinic
Updates on clinical development of peptide therapeutics.
Kathy Miller
Ballvé-Lantero Professor
Indiana University
Peptide vaccines for prevention and treatment of cancer
Jeff Alberts
Advisor Scientist-ADME
Eli Lilly and Company
The Journey of Bioanalytical Support for Peptides from Target of Interest to Post Market
Corey Adams
Chief Business Officer
NoNO Inc.
Clinical Development of a PSD-95 Inhibitor for Acute Ischemic Stroke
David Wagner
Assoc Professor/Chief Scientific Officer
University of Colorado Anschutz Medical Campus/ Op-T, LLC
OPT101, A Peptide Targeting CD40 – CD154 Interaction Completed Phase 1 Clinical Trial
Beverly Knight
Director
Johnson & Johnson Innovative Medicine
Translational Pharmacokinetics of Icotrokinra, an Orally Delivered Peptide that Inhibits the IL-23 Receptor
Drug Delivery
Novel approaches to peptide drug delivery including devices, molecular engineering, conjugation, and formulation technologies.
Guizhi Zhu
Associate Professor
University of Michigan
Engineer and deliver peptide-based proteolysis-targeting vaccines (PROTAX) for cancer immunotherapy
Zhigao Niu
Senior Scientist & Innovation Lead
Novo Nordisk
Efforts to improve the SNAC-based formulations for oral peptide delivery
Marvin Albers
PhD Student
VU Amsterdam
grabRNA: Smart RNA delivery enables novel therapeutic strategies
Christian Becker
Professor
University of Vienna
Targeted innate immune stimulators as therapeutics
Katerina Leftheris
Visiting professor/former CSO
Stony Brook University/Vilya, Inc.
Targeting Peptides and Macrocycles as Drugs: Novel approaches on the Horizon
Jie Zhang
Director of Chemsitry
Protagonist Therapeutics
PN-881: First-in-Class Oral Peptide Targeting the IL-17 Pathway
Spotlight on Discovery
This year’s Spotlight on Discovery is focused on peptide use in alcohol & drug addiction research.
Stephanie Seminara
Chief, Reproductive Endocrine Unit
Mass General Brigham
A Kiss to Remember
Jung-Mo Ahn
Associate Professor
University of Texas at Dallas
Structure-Based Design of Alpha-Helix Mimetics for Inhibiting Protein-Protein Interactions and Treating Breast Cancer
Christopher Ing
Chief Scientific Officer
ProteinQure Inc.
Structure-based Drug Design of a Novel Sortilin-Targeted Peptide Drug Conjugate with Efficacy in Preclinical Models of Breast Cancer
Chemistry of Complex Peptides
Akshay Shah
Director of Chemistry
Pinnacle Medicines
Enablement of Late-Stage Functionalization and High-Throughput Parallel Chemistry for Efficient Peptide Optimization
César de la Fuente
Presidential Associate Professor
University of Pennsylvania
Accelerating antibiotic discovery using AI
Søren Østergaard
Senior Principal Scientist
Novo Nordisk A/S
Half-life extension of peptides using fatty acid derivatization; past, present and future opportunities
Tom Tucker
Principal Scientist
Merck and Co., Inc.
Discovery of the Highly Potent and Orally Bioavailable Cyclic Peptide PCSK9 Inhibitor MK-0616
Christian Gruber
Assoc. Prof.
Medical University of Vienna
Peptide-based approaches to GPCR drug discovery: novel κ-opioid receptor ligands for applications in inflammatory pain
AI/Machine Learning with Peptides Workshop
Machine learning is rapidly transforming how we discover and design peptides, offering powerful tools to predict function and explore vast sequence spaces. This workshop will demystify key concepts in machine learning, from data preparation to model validation, and show how these techniques complement, rather than replace, human expertise. We’ll address common misconceptions and provide practical guidance on applying ML effectively in peptide research. Attendees will gain insights into model reliability, feature selection, data requirements, and the exciting generative capabilities of neural networks. Whether you’re new to machine learning or looking to deepen your understanding, this session will equip you with essential knowledge to harness its potential in your work.
Goran Mauša
Associate professor
University of Rijeka, Faculty of Engineering
AI/Machine Learning Workshop
Daniela Kalafatovic
Associate Professor
University of Rijeka
AI/Machine Learning Workshop
Panel Discussion: Peptides as Radiopharmaceuticals
Peptide-based radiopharmaceuticals represent a rapidly evolving class of agents for diagnostic imaging and targeted radionuclide therapy. Due to their high affinity for specific receptors overexpressed in tumors, peptides can selectively deliver radioactive isotopes to diseased tissues while minimizing off-target effects. Advances in solid-phase peptide synthesis (SPPS) and chelator chemistry have enabled the development of a wide array of radiolabeled peptides, including analogs of somatostatin, bombesin, neurotensin, and RGD. These agents are used in PET/SPECT imaging and Peptide Receptor Radionuclide Therapy (PRRT), with FDA-approved examples such as LUTATHERA®, NETSPOT®, and PLUVICTO®. Ongoing research focuses on improving pharmacokinetics, reducing renal toxicity, and expanding applications to other cancers through novel peptide sequences and radionuclide combinations.
There are no views with that ID
Sponsored Talk by Asymchem
Susan Li
Peptide Chief Scientist, CMC development and manufacturing
Asymchem Group
Forced Degradation Study of Peptides
Sponsored Talk by Gyros Protein Technologies
Dominik Sarma
Senior Market Manager
Gyros Protein Technologies
Simplified catch-and-release protocol transforms difficult-to-dissolve peptides into routine purifications
Sponsored Talk by CPC Scientific
John Phipps
VP of Clinical Pipeline Development
CPC Scientific
Reduction in Impurities Formed During Large-Scale Semaglutide Synthesis
Sponsored Talk by Bachem
Daniel Kessler
Sr. Group Leader Project Management
Bachem
CMC development for peptide API
Sponsored Talk by WuXi TIDES
Yvonne Angell
Executive Director, Discovery Chemistry Project Management
WuXi TIDES
Bridging Innovative Peptide Designs with Scalable, Manufacturable Solutions for Therapeutic Success